Study ID: ACCRU_BO25126_Aphinity
Description:

A Prospective, Randomized Multicenter, Multinational, Double-Blind Placebo Controlled Comparison of Chemotherapy Plus Trastuzumab and Placebo Given for a Total of One Year Versus Chemotherapy Plus Trastuzumab and Pertuzumab Given for a Total of One Year as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer

Location:
Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD
Disease:
Breast - Invasive
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list